Picture of IDEXX Laboratories logo

IDXX — IDEXX Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow

Oct 31 (Reuters) - IDEXX Laboratories  IDXX.O  trimmed
its annual revenue forecast for the third time on Thursday, as
the animal health diagnostic equipment maker sees fewer visits
to veterinary clinics from pet owners.

    
      WHY IT'S IMPORTANT
  
    IDEXX Labs' earnings come at a time when the animal health
sector experiencing a slowdown in pet clinic visits due to
inflationary pressures, alongside persistent staffing challenges
at veterinary clinics.
  

    
      KEY QUOTE
  
"We continue to see veterinary visit trend recovery as a matter
of when versus if and expect visits to return to the historical
2-3% growth over the next few years", said J.P. Morgan analyst
Chris Schott in a note.

    
      CONTEXT
  
Veterinary clinics continue to struggle after having faced
disruptions in the recent past, mainly caused by staffing
shortages over the past couple of years, as well as inflationary
pressures making pet owners cautious of spending.
    This is the third time the company has trimmed its full-year
forecast in the year, hurt by slower-than-expected growth in
veterinary clinic visits.

    
      BY THE NUMBERS
  
    The Westbrook, Maine-based company now expects full-year
revenue between $3.87 billion and $3.89 billion, down $38
million at the midpoint from its previous forecast. 
        IDEXX also narrowed its annual profit outlook to
$10.37-$10.53 per share from the previously expected range of
$10.31 and $10.59 per share.
    Analysts on average expected annual revenue of $3.92 billion
and earnings per share of $10.56, according to data compiled by
LSEG.
    Sales for its companion animal group unit, its biggest unit
which offers diagnostics for pets and IT services to veterinary
clinics, rose about 6% to $892 million in the quarter ended
September 30.
    The company reported total quarterly revenues of $976
million, up 7% year-over-year but below LSEG estimates of $979.2
million.
        Earnings per share for the quarter reached $2.80,
compared to $2.53 a year ago.
  

 (Reporting by Unnamalai L in Bengaluru; Editing by Tasim Zahid)
 ((Unnamalai.L@thomsonreuters.com;))

Recent news on IDEXX Laboratories

See all news